Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ryan Brown (Belfast, United Kingdom), Ryan Brown, Donna Small, Anthony Abladey, Leslie Holsinger, Robert Booth, Chris Scott, Stuart Elborn, Marcus Mall, Sinéad Weldon, Cliff Taggart. Investigating the role of cathepsin S in the pathogenesis of cystic fibrosis-like lung disease. Eur Respir J 2015; 46: Suppl. 59, 3903

Member's Comments

No comment yet.

Related content which might interest you: A role for cathepsin S in the pathogenesis of cystic fibrosis lung disease? Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 The role of CFTR/ENaC genotype in cystic fibrosis-like phenotypes Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 Genetics, pathophysiology and diagnosis of Cystic fibrosis Source: ERS Skills Course 2016 Year: 2016 MiR-214-3p, a new fibromiR involved in the pathogenesis of idiopathic pulmonary fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Increased systemic inflammation in cystic fibrosis (CF) is associated with deterioration in lung clearance index (LCI) Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Regulation of interleukin-8 by miR-17 during chronic inflammation in cystic fibrosis Source: International Congress 2015 – The multiple faces of host defense Year: 2015 New insights into the pathophysiology of lung disease in cystic fibrosis patients Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1 Year: 2006 Pathophysiology of cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 1-13 Year: 2014 Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Cystic fibrosis lung disease assessed by lung clearance index Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Targeting of cathepsin S reduces cystic fibrosis-like lung disease Source: Eur Respir J, 53 (3) 1801523; 10.1183/13993003.01523-2018 Year: 2019 Polymorphisms in NOS-1 and NOS-3 genes may influence the cystic fibrosis severity? Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014